Cited by

• CK2B is a Prognostic Biomarker and a Potential Drug Target for Hepatocellular Carcinoma.

  Dai H, Liu M, Pan Y, Li T, Pan Y, Chen ZS, Li J, Liu Y, Fang S. Dai H, et al. Recent Pat Anticancer Drug Discov. 2024;19(5):622-634. doi: 10.2174/0115748928262221230925090120. Recent Pat Anticancer Drug Discov. 2024. PMID: 37779404
• The ALBI score: From liver function in patients with HCC to a general measure of liver function.

  Toyoda H, Johnson PJ. Toyoda H, et al. JHEP Rep. 2022 Aug 18;4(10):100557. doi: 10.1016/j.jhepr.2022.100557. eCollection 2022 Oct. JHEP Rep. 2022. PMID: 36124124 Free PMC article. Review.
• The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.

  Ouyang J, Yang Y, Zhou Y, Ye F, Wang Z, Li Q, Xu Y, Li L, Zhao X, Zhang W, Zhou A, Huang Z, Wang Y, Cai J, Zhao H, Zhou J. Ouyang J, et al. Hepatol Int. 2023 Dec;17(6):1519-1531. doi: 10.1007/s12072-023-10580-3. Epub 2023 Sep 14. Hepatol Int. 2023. PMID: 37707759
• ALBI score combined with FIB-4 index to predict post-hepatectomy liver failure in patients with hepatocellular carcinoma.

  Tian YB, Niu H, Xu F, Shang-Guan PW, Song WW. Tian YB, et al. Sci Rep. 2024 Apr 5;14(1):8034. doi: 10.1038/s41598-024-58205-5. Sci Rep. 2024. PMID: 38580647 Free PMC article.
• Predictive value of preoperative albumin-bilirubin score and other risk factors for short-term outcomes after open pancreatoduodenectomy.

  Zavrtanik H, Cosola D, Badovinac D, Hadžialjević B, Horvat G, Plevel D, Bogoni S, Tarchi P, de Manzini N, Tomažič A. Zavrtanik H, et al. World J Clin Cases. 2023 Sep 16;11(26):6051-6065. doi: 10.12998/wjcc.v11.i26.6051. World J Clin Cases. 2023. PMID: 37731561 Free PMC article.